NNZ 2591|cas:847952-38-9|西域试剂

NNZ 2591,99.87%

产品编号：Bellancom-148195| CAS NO：847952-38-9| 分子式：C₁₀H₁₄N₂O₂| 分子量：194.23

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-148195		￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

NNZ 2591

产品介绍

NNZ 2591 是环状甘氨酸脯氨酸 (cGP) 小肽的合成类似物。NNZ 2591 具有口服活性并能穿过血脑屏障。NNZ 2591 在缺血性脑损伤后显示出神经保护作用。NNZ 2591 改善帕金森病大鼠模型的运动功能。NNZ 2591 具有研究缺血性脑损伤和天使综合征的潜力。

生物活性

NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome.

体外研究

体内研究

NNZ 2591 (30 mg/kg; p.o.) prevented scopolamine-induced memory impairment in rats.
NNZ 2591 (2, 20, 100 ng/rat; i.c.v.) shows neuroprotection in rats.
NNZ 2591 (3 mg/kg; s.c.; daily for 5 days) completely preventes brain damage and significantly reduces the L/R ratio of time taken to touch to the patch at 5 d after injury in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4 months, male young adult Wistar rats.
Dosage:	30 mg/kg
Administration:	P.o.; 10 min after the (scopolamine) i.p. administration.
Result:	Significantly reduced the number of M2AchR positive neurons, significantly reduced the density of synaptophysin in the CA3 and CA4 sub-regions, and altered TH terminal staining in the striatum.

Animal Model:	280-310 g adult male Wistar rats.
Dosage:	2, 20, 100 ng/rat
Administration:	I.c.v.; 2 h after HI injury
Result:	Reduced overall tissue damage in the sub-regions of the hippocampus, DG, cerebral cortex and the striatum.

Animal Model:	280-310 g adult male Wistar rats.
Dosage:	3 mg/kg
Administration:	S.c.; daily for 5 days
Result:	Significantly reduced the median of tissue damage scores in the CA1-2, CA3 and CA4 sub-regions of the hippocampus, the DG.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4 months, male young adult Wistar rats.
Dosage:	30 mg/kg
Administration:	P.o.; 10 min after the (scopolamine) i.p. administration.
Result:	Significantly reduced the number of M2AchR positive neurons, significantly reduced the density of synaptophysin in the CA3 and CA4 sub-regions, and altered TH terminal staining in the striatum.

Animal Model:	280-310 g adult male Wistar rats.
Dosage:	2, 20, 100 ng/rat
Administration:	I.c.v.; 2 h after HI injury
Result:	Reduced overall tissue damage in the sub-regions of the hippocampus, DG, cerebral cortex and the striatum.

Animal Model:	280-310 g adult male Wistar rats.
Dosage:	3 mg/kg
Administration:	S.c.; daily for 5 days
Result:	Significantly reduced the median of tissue damage scores in the CA1-2, CA3 and CA4 sub-regions of the hippocampus, the DG.

性状

Solid

溶解性数据

In Vitro:

DMSO : 18.75 mg/mL (96.54 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.1485 mL	25.7427 mL	51.4854 mL
5 mM	1.0297 mL	5.1485 mL	10.2971 mL
10 mM	0.5149 mL	2.5743 mL	5.1485 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.5 mg/mL (7.72 mM); Clear solution

此方案可获得 ≥ 1.5 mg/mL (7.72 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 15.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 1.5 mg/mL (7.72 mM); Suspended solution; Need ultrasonic

此方案可获得 1.5 mg/mL (7.72 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 15.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.5 mg/mL (7.72 mM); Clear solution

此方案可获得 ≥ 1.5 mg/mL (7.72 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 15.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。